FDA Accepts Isatuximab for Priority Review for Treatment of Transplant-Ineligible Multiple Myeloma

Isatuximab is used in combination with bortezomib, lenalidomide, and dexamethanose.

Related Keywords

United States ,Dietmar Berger ,Amgen Inc ,Zydus Pharmaceuticals Inc ,Janssen Pharmaceutical Companies ,